Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Kafrit Industries on acquisition of Addvanze
Mandate

Vinge advises Kafrit Industries on acquisition of Addvanze

May 11, 2021 Employment and Benefits Banking and Finance Intellectual Property IT, Telecommunications and Outsourcing M&A Real Estate and Construction Commercial Agreements

Vinge advises Kafrit Industries (1993) Ltd on acquisition of Addvanze AB.

Kafrit Industries (1993) Ltd is an innovative and world leading producer of customized Masterbatches and Compounds for the plastic industry. For over 40 years Kafrit and its subsidiaries have been selling unique products and giving added value to well known customers around the world. Addvanze AB is a leading producer of the masterbatch in Europe.

Vinge’s team consisted of, among others, partners Christina Kokko and Matthias Pannier and associates Isabelle Jengsell and Amanda Steen (M&A), Isabell Nielsen (Agreements), Ludvig Wettergren and Karl-Gustaw Tobola (Banking and finance), Sara Strandberg (Employment), Sofia Bergenstråhle (IPR), Karl-Hugo Engdahl (IT/GDPR), Lina Österberg (Real Estate and environment) and VDR assistant Nathalie Hughes.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025